SCHEMBL480387

SCHEMBL480387

COC(=O)c1ccc2c(c1)NC(=O)C2=C(Nc1ccc(C(C)(C)N)c([N+](=O)[O-])c1)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 2/20 0.39
KMT2A Q03164 5/20 0.37
CTDSP1 Q9GZU7 1/20 0.37
POLB P06746 2/20 0.37
TP53 P04637 1/20 0.37
THRB P10828 1/20 0.37
BLM P54132 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
VCAM1 P19320 1/20 0.36
MEN1 O00255 4/20 0.36
CHEK1 O14757 2/20 0.36
AKR1C4 P17516 1/20 0.36
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
AKR1C1 Q04828 1/20 0.36
CFTR P13569 1/20 0.35
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
GSK3B P49841 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL479442 0.92 SMN1; SMN2 (0.42) KMT2ACTDSP1POLBMEN1RAB9A
SCHEMBL2121532 0.87 KMT2A (0.40) KMT2ACTDSP1POLBTP53THRB
SCHEMBL480655 0.87 KMT2A (0.40) CASP3KMT2ACTDSP1POLBTP53
SCHEMBL479448 0.86 KMT2A (0.39) KMT2ACTDSP1POLBTP53THRB
SCHEMBL479595 0.86 BRD4 (0.40) CASP3KMT2ACTDSP1POLBTP53
SCHEMBL479436 0.86 MAPT (0.40) CASP3KMT2ACTDSP1POLBTP53
SCHEMBL479616 0.85 NOTUM (0.40) KMT2ACTDSP1POLBTP53THRB
SCHEMBL480718 0.85 KMT2A (0.38) KMT2ACTDSP1POLBTP53THRB
SCHEMBL3156586 0.84 MEN1 (0.50) CASP3KMT2APOLBMEN1RAB9A
SCHEMBL2119613 0.84 MEN1 (0.50) CASP3KMT2APOLBMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9844572-B2 Promotion of neuronal integration in neural stem cell grafts LIFE & BRAIN GMBH (DE) 2017-12-19 US disclosed
EP-2411034-B1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS LIFE & BRAIN GMBH (DE) 2017-07-26 EP disclosed
US-20120093832-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS LIFE & BRAIN GMBH (DE) 2012-04-19 US disclosed
EP-2411034-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS Life & Brain GmbH (DE) 2012-02-01 EP disclosed
WO-2010108665-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS LIFE & BRAIN GMBH (DE) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120093832-A1 PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS DCX, NGF, BDNF CASP3 3437/4885KMT2A 3904/4885CTDSP1 4624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.